Understanding HIV Drug Resistance to Create Better Medicines
A Systematic Toolkit for Counteracting HIV Drug Resistance with Protein Structural Dynamics
['FUNDING_R21'] · UNIVERSITY OF ILLINOIS AT CHICAGO · NIH-11145784
This project aims to understand why HIV medicines stop working for some people, so we can design new treatments that overcome drug resistance.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ILLINOIS AT CHICAGO (nih funded) |
| Locations | 1 site (Chicago, UNITED STATES) |
| Trial ID | NIH-11145784 on ClinicalTrials.gov |
What this research studies
HIV continues to be a major health challenge globally, partly because the virus can change and become resistant to current medications over time. Our current ways of understanding this resistance have limitations, often missing how drug molecules and viral proteins move and interact. This project uses advanced physics-based methods to precisely study how HIV drugs bind to the virus and how mutations in the virus lead to resistance. By gaining a deeper understanding of these processes, we hope to develop a rigorous approach for designing more effective antiviral drugs.
Who could benefit from this research
Good fit: This foundational research is ultimately for individuals living with HIV, especially those who may experience drug resistance to current treatments.
Not a fit: Patients who do not have HIV or are not concerned with drug resistance may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to the development of new and more effective HIV medications that are better at fighting drug-resistant forms of the virus.
How similar studies have performed: While previous approaches have led to some drug designs, this project proposes a novel, physics-based method to overcome their limitations in understanding drug resistance.
Where this research is happening
Chicago, UNITED STATES
- UNIVERSITY OF ILLINOIS AT CHICAGO — Chicago, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MA, AO — UNIVERSITY OF ILLINOIS AT CHICAGO
- Study coordinator: MA, AO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus